Outputs (6)

Sensory neuronal sensitisation occurs through HMGB-1/RAGE and TRPV1 in high glucose conditions (2018)
Journal Article
Bestall, S. M., Hulse, R. P., Blackley, Z., Swift, M., Ved, N., Paton, K., Beazley-Long, N., Bates, D. O., & Donaldson, L. F. (in press). Sensory neuronal sensitisation occurs through HMGB-1/RAGE and TRPV1 in high glucose conditions. Journal of Cell Science, Article jcs.215939. https://doi.org/10.1242/jcs.215939

Many potential causes for painful diabetic neuropathy have been proposed including actions of cytokines and growth factors. High mobility group protein B1 (HMGB1) is a RAGE agonist, increased in diabetes, that contributes to pain by modulating periph... Read More about Sensory neuronal sensitisation occurs through HMGB-1/RAGE and TRPV1 in high glucose conditions.

VEGFR2 promotes central endothelial activation and the spread of pain in inflammatory arthritis (2018)
Journal Article
Beazley-Long, N., Moss, C. E., Ashby, W. R., Bestall, S. M., Almahasneh, F., Durrant, A. M., Benest, A. V., Blackley, Z., Hirashima, M., Ballmer-Hofer, K., Hulse, R. P., Bates, D. O., & Donaldson, L. F. (2018). VEGFR2 promotes central endothelial activation and the spread of pain in inflammatory arthritis. Brain, Behavior, and Immunity, 74, 49-67. https://doi.org/10.1016/j.bbi.2018.03.012

Chronic pain can develop in response to conditions such as inflammatory arthritis. The central mechanisms underlying the development and maintenance of chronic pain in humans are not well elucidated although there is evidence for a role of microglia... Read More about VEGFR2 promotes central endothelial activation and the spread of pain in inflammatory arthritis.

Pharmacology of modulators of alternative splicing (2017)
Journal Article
Bates, D. O., Morris, J. C., Oltean, S., & Donaldson, L. F. (2017). Pharmacology of modulators of alternative splicing. Pharmacological Reviews, 69(1), https://doi.org/10.1124/pr.115.011239

More than 95% of genes in the human genome are alternatively spliced to form multiple transcripts, often encoding proteins with differing or opposing function. The control of alternative splicing is now being elucidated, and with this comes the oppor... Read More about Pharmacology of modulators of alternative splicing.

The control of alternative splicing by SRSF1 in myelinated afferents contributes to the development of neuropathic pain (2016)
Journal Article
Hulse, R. P., Drake, R. A., Bates, D. O., & Donaldson, L. F. (in press). The control of alternative splicing by SRSF1 in myelinated afferents contributes to the development of neuropathic pain. Neurobiology of Disease, 96, https://doi.org/10.1016/j.nbd.2016.09.009

Neuropathic pain results from neuroplasticity in nociceptive neuronal networks. Here we demonstrate that control of alternative pre-mRNA splicing, through the splice factor serine-arginine splice factor 1 (SRSF1), is integral to the processing of noc... Read More about The control of alternative splicing by SRSF1 in myelinated afferents contributes to the development of neuropathic pain.

Vascular endothelial growth factor-A165b is protective and restores endothelial glycocalyx in diabetic nephropathy (2015)
Journal Article
Oltean, S., Qiu, Y., Ferguson, J. K., Stevens, M., Neal, C., Russell, A., Kaura, A., Arkill, K. P., Harris, K., Symonds, C., Lacey, K., Wijeyaratne, L., Gammons, M., Wylie, E., Hulse, R. P., Alsop, C., Cope, G., Damodaran, G., Betteridge, K. B., Ramnath, R., …Salmon, A. H. (2015). Vascular endothelial growth factor-A165b is protective and restores endothelial glycocalyx in diabetic nephropathy. Journal of the American Society of Nephrology, 26(8), https://doi.org/10.1681/ASN.2014040350

Diabetic nephropathy is the leading cause of ESRD in high-income countries and a growing problem across the world. Vascular endothelial growth factor-A (VEGF-A) is thought to be a critical mediator of vascular dysfunction in diabetic nephropathy, yet... Read More about Vascular endothelial growth factor-A165b is protective and restores endothelial glycocalyx in diabetic nephropathy.

Vascular endothelial growth factor-A165b prevents diabetic neuropathic pain and sensory neuronal degeneration (2015)
Journal Article
Hulse, R. P., Beazley-Long, N., Ved, N., Bestall, S. M., Riaz, H., Singhal, P., Ballmer Hofer, K., Harper, S. J., Bates, D. O., & Donaldson, L. F. (2015). Vascular endothelial growth factor-A165b prevents diabetic neuropathic pain and sensory neuronal degeneration. Clinical Science, 129(8), https://doi.org/10.1042/CS20150124

Diabetic peripheral neuropathy affects up to half of diabetic patients. This neuronal damage leads to sensory disturbances, including allodynia and hyperalgesia. Many growth factors have been suggested as useful treatments for prevention of neurodege... Read More about Vascular endothelial growth factor-A165b prevents diabetic neuropathic pain and sensory neuronal degeneration.